First-in-human data from a study into a radioligand therapy (RLT) targeting metastatic breast cancer is set to be announced. Radiopharmaceutical company Affibody will present the data on ABY-271, the HER2-targeting RLT candidate, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting. The event will… Read More
Fredrik Frejd, Chief Scientific Officer at Affibody, explains how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches. The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis’ Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over… Read More
Swedish radiopharmaceuticals company Affibody Medical has secured SEK 307 million ($34 million) by carrying out a fully guaranteed rights issue. Affibody’s main shareholder Patricia Industries, part of Investor AB, has via its subsidiary Duba AB committed to subscribe for its pro rata share, as well as any… Read More
Affibody has shared the results of preclinical studies with its radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2-expressing metastatic disease. The data were presented at the Annual Congress of the European Association of Nuclear Medicine by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Read More
